April 26, 2021 marks the 21st World Intellectual Property Day. Hansoh Pharma adheres to the innovation-driven development strategy. Since its inception, Hansoh Pharma has been well aware of the importance of independent innovation, and has attached great importance to IP development and accumulation. Relying on its solid R&D strength and sophisticated management system, the company has persistently tackled technical barriers in scientific research, developed a large number of key core technologies, obtained a batch of core high-value drug patents, promoted the development and upgrading of China's pharmaceutical industry, and brought benefits to the health and quality of life of Chinese people. 

It is indeed the persistence in innovation and the emphasis on IP that have led to Hansoh Pharma' impressive IP results in recent years. Up to now, the Company has four innovative drugs with independent IP rights approved to market for the benefit of patients; has won two National Science and Technology Progress Awards, one China Patent Gold Award, one China Patent Silver Award, and six China Patent Excellence Awards; has successively undertaken nearly 40 major science and technology projects under the Major New Drug Innovations initiative, and obtained more than 300 authorized invention patents at home and abroad; and has been recognized as a national IP demonstration enterprise. 

Upholding the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma will keep pushing in-depth implementation of its IP strategy, improve the level of IP management, enhance its independent innovation capability and core competitiveness, accelerate the pace of transformation and upgrading, and help grow China's pharmaceutical industry to a higher level. 

Protecting IP assets

Protecting the source of innovation

2021.4.26

World Intellectual Property Day